Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart
about
Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growthSingle-stranded DNA-binding proteins PURalpha and PURbeta bind to a purine-rich negative regulatory element of the alpha-myosin heavy chain gene and control transcriptional and translational regulation of the gene expression. Implications in the repActivated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy.Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathyAlterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathyGenetics of congenital heart disease: the glass half emptyA Murine Myh6MerCreMer Knock-In Allele Specifically Mediates Temporal Genetic Deletion in Cardiomyocytes after Tamoxifen InductionProtein kinase C epsilon signaling complexes include metabolism- and transcription/translation-related proteins: complimentary separation techniques with LC/MS/MSA calcineurin-dependent transcriptional pathway for cardiac hypertrophyFunctional significance of cardiac myosin essential light chain isoform switching in transgenic miceCardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudineDilated cardiomyopathy in homozygous myosin-binding protein-C mutant miceCardiac myosin-binding protein-C phosphorylation and cardiac functionImpaired cardiac hypertrophic response in Calcineurin Abeta -deficient miceSerotonin 2B receptor is required for heart developmentInteraction of Gata4 and Gata6 with Tbx5 is critical for normal cardiac developmentAbsence of heartbeat in the Xenopus tropicalis mutation muzak is caused by a nonsense mutation in cardiac myosin myh6Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor.Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice.Myofibril degeneration caused by tropomodulin overexpression leads to dilated cardiomyopathy in juvenile mice.Cardiac compartment-specific overexpression of a modified retinoic acid receptor produces dilated cardiomyopathy and congestive heart failure in transgenic mice.Genome-wide differential gene expression in immortalized DF-1 chicken embryo fibroblast cell lineProgression from hypertrophic to dilated cardiomyopathy in mice that express a mutant myosin transgene.Alpha1A-adrenergic receptor-directed autoimmunity induces left ventricular damage and diastolic dysfunction in rats.Quantitative trait loci for exercise training responses in FVB/NJ and C57BL/6J mice.Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure.The molecular genetic basis for hypertrophic cardiomyopathy.Direct and indirect protection of right ventricular function by estrogen in an experimental model of pulmonary arterial hypertension.Molecular genetics and pathogenesis of hypertrophic cardiomyopathy.Cardiac-specific NRAP overexpression causes right ventricular dysfunction in miceHeme oxygenase-1 induction enhances cell survival and restores contractility to unvascularized three-dimensional adult cardiomyocyte grafts implanted in vivo.Electrophysiological phenotyping in genetically engineered mice.Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney.The Mef2A transcription factor coordinately regulates a costamere gene program in cardiac muscle.Lymphocyte responses exacerbate angiotensin II-dependent hypertension.Evaluation of Cardioprotective Effect of 3,5,3'-Tri-iodo-L-thyronine in Isoproterenol-Induced CardiotoxicityTransgenic mice with cardiac-specific expression of activating transcription factor 3, a stress-inducible gene, have conduction abnormalities and contractile dysfunctionProteomic Profiling of Early Chronic Pulmonary Hypertension: Evidence for Both Adaptive and Maladaptive Pathology.Cardiac myosin binding protein-C: redefining its structure and function.Dual function of the UNC-45b chaperone with myosin and GATA4 in cardiac development
P2860
Q24309615-9CB424D3-102B-4546-BA3F-8D6237240077Q24317565-9A40D497-6DE8-4580-976F-2FC65E43DA7EQ24535352-51A98834-6C5A-4976-94E5-7504621B7F84Q24562178-8EF6B6ED-CC6B-487B-8943-420258B185DEQ24680224-1919CDD6-8AF6-409E-9013-14829ACF9936Q26862793-66712B8C-FFD6-46FC-9451-6BBDA1EC9E8AQ27302178-F0F25C54-EFB4-481E-93DA-24C5C24B66EDQ28217272-57C03051-5C43-4D16-BEA8-B6C662EB6120Q28269300-14B4FB3F-2243-4E1A-A3D6-867BB5638474Q28274535-0671408D-708E-44C0-8D4C-BC27FB42C3D3Q28372167-FB4B7310-7D2F-4ACF-AE5B-A162D04DD91DQ28505121-8839D9C2-F6DB-488D-A949-CE5F5EDAA944Q28584863-3A66E734-8D8F-4E8F-812B-BB8FAE9C51BDQ28587028-BEEE1398-65D1-4DC7-BA07-13F620D9E16CQ28594131-A5B549B0-C0BC-4BE5-8B9E-581DAD7A67FEQ28594374-E2A31E87-B0DC-453A-8E85-9058FDBAA75CQ30433963-AC399BD5-5377-4FD6-8259-B7FFA92D1FB3Q30453517-C4AEC9C0-DE36-409D-A8C2-15F397518155Q30500669-6731F4C4-421D-412C-BCBE-311149B39853Q30500685-A34B07C7-6C65-47FC-8874-8CDE0F856CEBQ30500687-447CEE59-9C33-47A1-AFB6-1A80CD6CE068Q31042174-3096FDBD-9C57-4569-9459-307AA7D84DEEQ31722329-92101C96-1561-4FB3-98FD-989492D8D0BAQ33535920-B5C5BA5D-DFB9-4945-9558-330FDB63696DQ33593470-A3D90963-B4D8-46EA-8F46-A5D526AD6171Q33853316-F83341CE-27BE-4EED-B587-1D892C7AB69EQ33939892-E64DB1FC-0D9E-473F-A851-CB47EF571CDAQ34001723-CA7D5B5D-CEB2-4F03-9B35-8EC9B02751BFQ34021080-F7AB4E56-BD36-4487-8F10-1079D26A66DBQ34762120-05116975-87A5-4E8B-B375-BE4FF678CA2FQ34995661-2F5C5860-8F19-4C66-9CDD-4A8D9089AE5CQ35127289-B15B2B22-2C8E-42DB-B869-5A23E2A2B107Q35215135-B43BD4C6-6532-4C18-BFE9-4C7A70D302B2Q35313641-388084F7-4C9E-43E4-9E48-D183288E1FA8Q35576468-26ACD9D9-44B6-4D61-A54F-069AD0F19505Q35582474-4A7CAFB1-F736-4BC3-9D50-CDB4C3963FB9Q35747029-5273B8C2-4C3A-4C9F-A517-6767D159A148Q35911593-F219D1FD-9818-4B08-BD4D-62FBD183E150Q36030150-3632C23F-CD5F-4EBD-9397-7D4E2624CC79Q36290852-887AAF9F-1FD7-438D-8C8E-0301E696BBB6
P2860
Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart
description
1996 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
article scientifique
@fr
articolo scientifico
@it
artículu científicu espublizáu en 1996
@ast
im Oktober 1996 veröffentlichter wissenschaftlicher Artikel
@de
scientific article
@en
vedecký článok (publikovaný 1996/10/15)
@sk
vědecký článek publikovaný v roce 1996
@cs
wetenschappelijk artikel (gepubliceerd op 1996/10/15)
@nl
name
Ablation of the murine alpha m ...... nctional deficits in the heart
@ast
Ablation of the murine alpha m ...... nctional deficits in the heart
@en
Ablation of the murine alpha m ...... nctional deficits in the heart
@nl
type
label
Ablation of the murine alpha m ...... nctional deficits in the heart
@ast
Ablation of the murine alpha m ...... nctional deficits in the heart
@en
Ablation of the murine alpha m ...... nctional deficits in the heart
@nl
prefLabel
Ablation of the murine alpha m ...... nctional deficits in the heart
@ast
Ablation of the murine alpha m ...... nctional deficits in the heart
@en
Ablation of the murine alpha m ...... nctional deficits in the heart
@nl
P2093
P2860
P356
P1476
Ablation of the murine alpha m ...... nctional deficits in the heart
@en
P2093
H. Osinska
I. L. Grupp
J. Robbins
T. Doetschman
T. E. Hewett
W. K. Jones
P2860
P304
P356
10.1172/JCI118992
P407
P577
1996-10-15T00:00:00Z